arrow
N

Nicola Normanno

fondazione policlinico universitario agostino gemelli irccs
H指数:76
被引数:3.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial

一线纳武利尤单抗联合FOLFOXIRI/贝伐珠单抗治疗RAS/BRAF突变型晚期结直肠癌:NIVACOR II期试验的疗效、安全性和生物标志物发现

2026-03-250
OAAI
Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma

Radiopsy:一项关于定量多参数全身磁共振成像以区分冒烟型骨髓瘤和多发myeloma的前瞻性观察研究

2025-12-011
OAAI
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

微卫星稳定型结直肠癌中高肿瘤突变负荷的基因组分析揭示了抗-EGFR治疗后MAPK信号通路的改变

2025-10-280
OAAI
Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper

肿瘤学中预测性生物标志物的间接临床验证:国际病理学质量网络(IQN Path)立场文件

2025-07-170
OA
Editorial Expression of Concern to: TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction

编者按:对TGF-β1暴露诱导A549细胞系中的CSCs和非CSCs发生上皮-间质转化,导致CD133+ A549细胞亚群迁移能力增强表示关注。

2025-07-020
OAAI
Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access

克服阻碍先进生物分子技术发展的壁垒,以指导实体瘤治疗:一条获取途径的路线图

2025-05-080
PRE
Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper

在临床实践中检测结直肠癌的BRAF突变: 意大利专家的立场文件

2025-02-011
OAAI
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
2024-12-011
PRE
Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion-positive glioblastoma
2024-11-200
OAAI
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial
2024-07-010
PRE
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group

晚期癌症2024年患者使用下一代测序 (NGS) 的建议: 来自ESMO精密医学工作组的报告

2024-07-0121
OAAI